Biomarker ID | 1480 |
PMID | 25075250 |
Year | 2014 |
Biomarker | miR-219 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: nucleoplasm; positive regulation of metabolic process; positive regulation of cellular metabolic process; DNA-binding transcription factor activity, RNA polymerase II-specific; anatomical structure morphogenesis |
Experiment | Benign Vs Malignant |
Type of Biomarker | Diagnostic |
Cohort | 215 samples were chosen for analysis. 204 were malignant and 11 were benign |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.004 |
Method Used | In Situ hybridization (ISH) |
Clinical | No |
Remarks | Results for epithelial carcinoma cell study |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |